MS clinical trial design for the future

Multiple Sclerosis

Volumn 1, Issue 6, 1996, Pages 393-399

  Goodkin, Donald E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Multiple sclerosis

Indexed keywords

EPIDEMIOLOGY; FORECASTING; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; REMISSION; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; EPIDEMIOLOGIC RESEARCH DESIGN; FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0030178497     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100623     Document Type: Article

References (27)

1. Whitaker JN et al. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1: 37-47.
2. CFR Title 21, Chapter I, Subchapter D, Part 312.21 (revised 04/01/94)
3. Willoughby EW, Paty DW. (1988) Scales for rating impairment in multiple sclerosis: a critique. Neurology 38: 1739-1738.
4. Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
5. Goodkin DE. (1994) Interferon beta-1b. Lancet 344: 1057-1060.
6. Goodkin DE et al. (1992) Inter-and intrarater scoring agreement using grades 1.0-3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 42: 859-863.
7. Noseworthy JH et al. (1990) Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 40: 971-995.
8. Amato MP et al. (1988) Interrater reliability in assessing function systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 45: 746-748.
9. Goodkin DE, Fischer J (in press). Treatment of multiple sclerosis with methotrexate. In; Multiple Sclerosis: Advances in clinical trial design, treatment and future perspectives (Eds) Goodkin DE, Rudick RA. Springer-Verlag: London.
10. Jacobs LD et al. (1995) A phase III trial of intramuscular recombinant Interferon beta as treatment for exacerbating remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis 1: 118-135.
11. Goodkin DE et al. (1988) Upper extremity function in multiple sclerosis: improving assessment sensivity with box-and-block and nine-hole-peg tests. Arch Phys Med Rehabil 69: 850-854.
12. Goodkin DE et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive MS. Ann Neurol 37: 30-40.
13. Goodkin DE et al. (1992) Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis: design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. Online J Curr Clin Trials [serial online] Sep 25 (Doc no 19).
14. Grossman RI. (In press) Magnetic resonance imaging: current status and strategies for improving MS clinical trial design. In; Multiple Sclerosis: Advances in clinical trial design, treatment and future perspectives (Eds;) Goodkin DE, Rudick RA. Springer-Verlag: London.
15. Sharief MK, Hentgew R. (1991) Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467-472.
16. Adachi K et al. (1990) Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol 28: 687-691.
17. Hartung HP. (1993) Immune-mediated demyelination. Ann Neurol 33: 563-567.
18. Whitaker JN et al. (1995) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 38: 625-632.
19. Filippi M et al. (1994) Quantitative brain MRI lesion load predict the course of clinically isolated syndromes suggestive of MS. Neurology 44: 635-641.
20. Khoury SJ et al (1994) Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 44: 2120-2124.
21. Paty DW et al. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667.
22. Kermode AG et al. (1990) Breakdown of the blood-brain-barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical impressions. Brain 113: 1477-1489.
23. Smith ME et al. (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine enhancing magnetic resonance imaging lesions. Ann Neurol 33: 480-489.
24. Miller DH et al. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116: 1077-1094.
25. Stone LA et al. (1995) Blood brain barrier disruption as measured by contrast enhanced MRI in patients with mild relapsing remitting multiple sclerosis: relationship to course, gender, and age. Neurology 37: 611-619.
26. Willoughby EW et al. (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 25: 43-49.
27. Albert PS et al. (1994) Time series for modeling counts from a relapsing-remitting disease: application to modeling disease activity in multiple sclerosis. Stat Med 13: 453-466.